Literature DB >> 12729069

Lipoprotein lipase during heparin infusion: lower activity in hemodialysis patients.

B Näsström1, G Olivecrona, T Olivecrona, B G Stegmayr.   

Abstract

BACKGROUND: [corrected] Patients on hemodialysis often have a moderate hypertriglyceridemia in combination with low HDL cholesterol. A contributing factor may be a derangement of the lipoprotein lipase (LPL) system. During dialysis, with heparin as anticoagulant, the enzyme is released into the circulating blood.
METHODS: We have followed LPL activity and triglycerides during ordinary heparin administration in nine hemodialysis patients and controls matched for age and gender. Blood samples were drawn before heparin administration and at 15, 30, 60, 120, 180 and 240 min.
RESULTS: LPL activity peaked at 15 or 30 min and then decreased to a plateau that was only 20%, of the peak. The activity was reduced in the patients by about 50% during the peak, and about 20% during the following plateau. During the peak of lipase activity the triglycerides decreased in both groups, but the change was less pronounced in patients, as was expected from the lower circulating lipase activity. During the plateau phase with low lipase activity, the triglycerides increased towards baseline values.
CONCLUSIONS: During hemodialysis with heparin, there is a peak in LPL activity as well as a reduction in triglycerides during the first hour. Thereafter LPL activity decreases towards a plateau, while triglycerides increase towards baseline. The peak activity of LPL in the patients was only half that in controls, while the plateau was comparable. The data indicate that during and following each dialysis there is a period when LPL activity becomes depleted to a level that is limiting for normal lipoprotein metabolism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12729069     DOI: 10.1080/00365510310000484

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  7 in total

1.  Dialysis Modalities and HDL Composition and Function.

Authors:  Michael Holzer; Gernot Schilcher; Sanja Curcic; Markus Trieb; Senka Ljubojevic; Tatjana Stojakovic; Hubert Scharnagl; Chantal M Kopecky; Alexander R Rosenkranz; Akos Heinemann; Gunther Marsche
Journal:  J Am Soc Nephrol       Date:  2015-03-05       Impact factor: 10.121

Review 2.  Anticoagulation in CKD and ESRD.

Authors:  Kelvin Cheuk-Wai Leung; Jennifer Marie MacRae
Journal:  J Nephrol       Date:  2019-01-28       Impact factor: 3.902

Review 3.  Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis.

Authors:  Jenny I Shen; Wolfgang C Winkelmayer
Journal:  Am J Kidney Dis       Date:  2012-05-05       Impact factor: 8.860

4.  Lipoprotein lipase in hemodialysis patients: indications that low molecular weight heparin depletes functional stores, despite low plasma levels of the enzyme.

Authors:  Birgit Näsström; Bernd Stegmayr; Gunilla Olivecrona; Thomas Olivecrona
Journal:  BMC Nephrol       Date:  2004-11-03       Impact factor: 2.388

Review 5.  Uremic toxins and lipases in haemodialysis: a process of repeated metabolic starvation.

Authors:  Bernd Stegmayr
Journal:  Toxins (Basel)       Date:  2014-04-30       Impact factor: 4.546

Review 6.  Dialysis Procedures Alter Metabolic Conditions.

Authors:  Bernd Stegmayr
Journal:  Nutrients       Date:  2017-05-27       Impact factor: 5.717

7.  The effect of citrate dialysate on intradialytic heparin dose in haemodialysis patients: study design of a randomised controlled trial.

Authors:  Davina J Tai; Kelvin Leung; Pietro Ravani; Robert R Quinn; Nairne Scott-Douglas; Jennifer M MacRae
Journal:  BMC Nephrol       Date:  2015-08-25       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.